Shannon Townsend, PA-C

In the final episode, ‘Emerging Therapies and the Future of EoE Care,’ the panelists explored the evolving treatment landscape in eosinophilic esophagitis and reflected on key principles clinicians can apply to improve patient care. The expert faculty discussed their optimism surrounding investigational therapies with novel mechanisms of action and the potential for a broader therapeutic pipeline to provide more individualized options for patients with EoE.

Emerging Therapies and the Future of EoE Care

The panel highlighted growing interest in targeting pathways beyond eosinophils alone, including mechanisms that may address other contributors to inflammation such as mast cells. They also discussed the importance of evaluating emerging therapies across multiple dimensions of disease, recognizing that symptoms, endoscopic findings, and histologic response may not always align. As additional treatment options become available, the panelists considered how therapies with different mechanisms could provide opportunities to better match treatment to individual disease characteristics and potentially address coexisting atopic conditions.

To close the series, the expert faculty reflected on the most important lessons from the broader discussion. They emphasized recognizing EoE as a chronic disease that requires ongoing management and building a strong clinician-patient partnership from the initial visit. Thorough assessment of symptoms, adaptive eating behaviors, comorbidities, lifestyle, and treatment preferences can help establish a foundation for individualized care and sustained engagement over time.

Ultimately, the panel emphasized treating EoE comprehensively rather than relying on a single measure of response. Integrating the patient experience with endoscopic and histologic assessment, while maintaining regular communication and shared decision-making, can help clinicians support meaningful disease control throughout the long-term treatment journey. Thank you for watching this HCPLive Peer Exchange series on eosinophilic esophagitis. Please subscribe to our eNewsletter for information on upcoming video series.

Videos

As the EoE treatment landscape expands, new therapeutic targets may create opportunities for more individualized care. The panel closes the series by connecting emerging science with practical principles for improving long-term EoE management.

This episode, titled ‘Overcoming Treatment Access Barriers in EoE,’ features panelists discussing system-level challenges that can affect timely access to treatment and monitoring for patients with eosinophilic esophagitis. The expert faculty examine how insurance requirements, prior authorization processes, medication costs, and coverage limitations can delay treatment initiation or create additional burdens for patients navigating long-term EoE care.

Overcoming Treatment Access Barriers in EoE

The panelists share practical approaches they use to anticipate and address these barriers in clinical practice. They highlight the value of involving clinical pharmacy and administrative teams early in the treatment process to facilitate prior authorizations and reduce unnecessary delays. Clear and comprehensive documentation is also emphasized, particularly when communicating the rationale for a selected therapy, previous treatment history, and relevant endoscopic and histologic findings to insurers.

Beyond medication access, the panel discusses financial barriers associated with ongoing disease monitoring. They describe situations in which insurance coverage or patient costs may limit access to repeat endoscopy, creating challenges when clinicians need objective measures to assess treatment response and disease control. The panelists also emphasize transparency with patients about potential delays and out-of-pocket costs so expectations can be established early in the treatment process. Finally, the expert faculty discuss available resources that may help patients navigate affordability concerns, including copay support and patient assistance programs. Throughout the episode, the panel underscores the importance of a coordinated, team-based approach involving clinicians, pharmacists, administrative staff, and patients to navigate access barriers and help patients receive appropriate EoE treatment and follow-up care.

In the next episode, ‘Emerging Therapies and the Future of EoE Care,’ panelists will explore investigational therapies that may expand the EoE treatment landscape and enable increasingly individualized care. They also reflect on key takeaways from the series, emphasizing comprehensive disease assessment, long-term management, and clinician-patient partnership.

Access can determine whether an effective EoE treatment plan becomes a reality. The expert faculty discuss practical strategies for navigating coverage, cost, and authorization barriers to support timely care.

In ‘Strategies to Improve Treatment Adherence in EoE Care,’ our panel explores strategies for selecting treatments that patients can realistically incorporate into their daily lives and remain adherent to over time. The expert faculty emphasize shared decision-making as a central component of adherence, highlighting the importance of giving patients an active role in choosing among available EoE treatment approaches.

Strategies to Improve Treatment Adherence in EoE Care

The panelists discuss how treatment selection should account for individual preferences, routines, and the practical demands associated with each option. Rather than expecting patients to make an immediate decision during an office visit, the panel describes giving patients time to consider how different therapies may fit into their lifestyle. This may include thinking about whether dietary changes are sustainable long term or whether a patient is comfortable committing to a daily medication regimen. By identifying potential barriers before treatment begins, clinicians can work with patients to select an approach they are more likely to maintain.

The discussion also highlights the value of clear communication and continued engagement after the initial visit. The panelists describe providing written information and patient education materials that allow individuals to review treatment options, potential adverse effects, and other considerations at their own pace. Follow-up through patient portals can then provide an opportunity to answer additional questions, revisit concerns, and move treatment decisions forward. Throughout the episode, the panel of experts underscores that adherence begins with selecting a treatment that is both clinically appropriate and feasible for the individual patient. Incorporating patient preferences, education, and ongoing communication into treatment decisions can help support sustained engagement with EoE therapy over time.

Our next episode, ‘Overcoming Treatment Access Barriers in EoE,’ examines the insurance, cost, and authorization challenges that can delay treatment and monitoring for patients with EoE. The panelists share practical strategies for navigating these barriers through clear documentation, patient communication, financial assistance resources, and team-based support.

Adherence starts with finding a treatment patients can realistically sustain. The expert faculty discuss how shared decision-making and patient education can help translate an EoE treatment plan into long-term action.

In this episode, ‘Adjusting Treatment and Quality of Life in EoE,’ the panelists explore how clinicians can approach treatment modification when eosinophilic esophagitis is no longer adequately controlled and how quality-of-life considerations can inform long-term management. The expert faculty first discuss the importance of determining why a patient has lost disease control, including whether treatment adherence, changes in dosing, insurance barriers, or other factors may be contributing to loss of histologic response.

Adjusting Treatment and Quality of Life in EoE

When a change in therapy is needed, the panelists emphasize returning to a patient-centered approach and reassessing both disease characteristics and individual treatment priorities. They discuss how symptoms, endoscopic and histologic findings, fibrostenotic features, and prior treatment response can help determine whether to optimize the current approach or consider another treatment option. The panel also highlights the importance of revisiting patient preferences over time, recognizing that lifestyle, priorities, and willingness to pursue different therapies may change throughout the course of a chronic disease.

The discussion then broadens to quality of life and its role in long-term EoE management. The panelists examine how symptoms and adaptive behaviors can affect eating, social activities, travel, work, and emotional well-being, while treatment costs, medication access, and the burden of repeated endoscopies can create additional challenges. Throughout the conversation, the expert faculty emphasize shared decision-making and the value of selecting therapies that not only achieve disease control but also remain practical and sustainable for the individual patient. By regularly reassessing both clinical response and the patient's experience, clinicians can personalize long-term EoE management as needs evolve.

The next episode in this series, ‘Strategies to Improve Treatment Adherence in EoE Care,’ features the panelists discussing how shared decision-making, patient education, and consideration of lifestyle and treatment preferences can support adherence. They highlight practical strategies for helping patients select and sustain an EoE treatment approach that works for them.

Effective EoE management requires more than controlling disease activity. The panel explores how evolving clinical needs and quality-of-life considerations can guide treatment decisions over time.

Shannon Townsend, PA-C

Articles